Authors
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
OlympiA: Adj Olaparib Post (Neo) Adjuvant Chemo in Pts with Germline BRCA1/BRCA2 & High Risk HER2-negativePanelists discuss the OlympiA trial, evaluating adjuvant olaparib post-neoadjuvant chemotherapy in patients with germline BRCA1/BRCA2 mutations and high-risk HER2-negative breast cancer, and its impact on treatment outcomes.
Latest:
Future Directions and Unmet Needs in T-ALLBijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Real-World Data Reveal Longer PFS With Elacestrant in Breast CancerSeth Wander, MD, PhD, discusses the extended survival with elacestrant in a real-world, which was longer than the randomized phase 3 trial data.
Latest:
Pandemic Leads to Delays in Crucial Early Cancer Screening TestsClayton Lau, MD, discusses the consequences of patients delaying cancer screenings due to fears of COVID-19.
Latest:
Addressing Clinical Trial Challenges in the Outpatient SettingThe national shortage of nurses and health care support staff has spilled over to the clinical research space.
Latest:
Important Safety Data Evaluated in Meta-Analysis of MyelofibrosisJan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.
Latest:
Using Comprehensive Genomic Profiling to Identify Rare Subsets of Merkel Cell CarcinomaRyan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.
Latest:
Therapies With Different Mechanisms of Action Available for Low-Risk MDSBertrand Y. Tuan, MD, discusses the therapies relevant to patients with low-risk myelodysplastic syndrome.
Latest:
EP. 6B: Clinical Experience With Trilaciclib in Patients With Extensive-Stage Small Cell Lung CancerIn this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.
Latest:
SEQUOIA Arm D Study: Zanubrutinib plus Venetoclax in Treatment-Naive CLL/SLL with del(17p) and/or TP53 MutationsA blood cancer specialist discusses the latest data from the SEQUOIA Arm D trial investigating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.
Latest:
Using AI to Enhance Cancer Diagnostics and TreatmentDavid Craig, PhD, discusses how AI is transforming cancer histopathology.
Latest:
Integrating Physician Opinions Into DLBCL Treatment SelectionPatrick Connor Johnson, MD, discusses what physicians take into consideration when integrating third-line treatment options in diffuse large B-cell lymphoma
Latest:
T-DXd as Second-Line Standard in HER2+ Metastatic Breast Cancer Supported by Subgroup AnalysisFam-trastuzumab deruxtecan-nxki led to prolonged progression-free survival and higher responses compared with ado-trastuzumab emtansine as second-line therapy in patients with HER2-positive metastatic breast cancer.
Latest:
Exploring the Need for Second-Line Treatments in Thyroid CancerCesar Augusto Perez, MD, discusses one of the top unmet needs that exists in the thyroid cancer space.
Latest:
About the C-800 Trial of Botensilimab/Balstilimab in Ovarian CancerBruno Bockorny, MD, discusses the phase 1 C-800 trial of botensilimab plus bastilimab, specifically for patients in the C-800-01 cohort with recurrent platinum refractory/resistant ovarian cancer.
Latest:
Medicaid Cuts Create Barriers for Oncologists and Patients With CancerGwen Nichols, MD, discussed the impact of Medicaid reductions on patient care and how oncologists can advocate for accessible cancer treatment during these uncertain times.
Latest:
Ongoing studies of Ra-223–based combinationsAn expert discusses other ongoing investigations exploring radium-223-based combinations for the treatment of metastatic castration-resistant prostate cancer, highlighting key studies and their potential impact on clinical practice.
Latest:
Genetic Risk Score Revolutionizes TNBC Prediction in Black WomenHolly Pederson, MD, and Elisha Hughes, PhD, discuss the findings and implications of a study evaluating risk of triple-negative breast cancer for Black women presented at the 2024 ASCO Annual Meeting.
Latest:
Future Outlook in Front-line Treatment for uHCC.James J. Harding, MD, discusses the remaining unmet needs in the first-line (1L) treatment space for unresectable hepatocellular carcinoma (uHCC) and how 1L immunotherapy (IO) combinations like nivolumab plus ipilimumab (NIVO + IPI) may help address these gaps, while highlighting unanswered questions and offering clinical pearls for managing uHCC.
Latest:
Predicting Palbociclib Outcomes in Breast Cancer Using Deep LearningXiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.
Latest:
An Update on Current and Emergent Therapies for Essential ThrombocytosisThe therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.
Latest:
Handling GI Toxicities While Using Selinexor Triplet Therapy in RRMMAdam Binder, MD, discusses how to handle gastrointestinal toxicities for patients with relapsed/refractory multiple myeloma who are on the triple therapy of selinexor, bortezomib, and dexamethasone.
Latest:
Imetelstat and Canakinumab in Lower-Risk MDSDrs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.
Latest:
Dysphagia-Optimized IMRT Shows Significance in Head and Neck CancerChristopher Nutting, MD, discusses the results of a randomized phase 3 trial using dysphagia-optimized intensity modulated radiotherapy versus standard IMRT in patients with head and neck cancer.
Latest:
Steroid Therapy for cGVHDPanelists discuss how steroid dosing for chronic graft-vs-host disease (cGVHD) typically starts at 0.5-1 mg/kg/day depending on severity, with careful tapering to avoid flares.
Latest:
Clinical Considerations with Axtilimab in R/R GVHDPanelists discuss how clinical considerations shape the use of axatilimab in relapsed or refractory graft-versus-host disease, addressing factors that influence its application and management in practice.
